GI Cancers: Hot Topics in 2024

Yale Cancer Center

J. Lacy

ESMO 2024 Summary: Late-Line Therapy in mCRC - How to Choose

2024 ESMO Annual Meeting Insights Hub

H. Hochster

ESMO 2024 Summary: Neoadjuvant Colon Cancer Treatment - Recent Clini…

2024 ESMO Annual Meeting Insights Hub

J. Taieb

The Importance of 1L Biomarkers in CRC

Nicholas DeVito

ESMO 2024 Summary: Highlights in CRC and Impacts on Practice

2024 ESMO Annual Meeting Insights Hub

R. Kim, T. Biachi

ESMO 2024 Summary: Developmental Therapeutics Highlights

2024 ESMO Annual Meeting Insights Hub

G. Sonpavde

ASCO® 2024 Summary: "CRC Key Studies Including TRANSMET, CheckMate 8…

2024 ASCO® Annual Meeting Insights Hub

R. Kim, T. Biachi

ASCO® 2024 Precision Medicine Highlights: LAURA and CROWN Trials (NS…

2024 ASCO® Annual Meeting Insights Hub

V. Subbiah

Clinical Implications of Tumor Agnostic Therapies

Shivaani Kummar

1L Botensilimab + Balstilimab in Stage IV MSS CRC Without Liver Mets…

Nicholas DeVito

History of Cancer and Its Treatment: What Will It Take to Cure?

University of Colorado Cancer Center

C. Lieu

ASCO® 2024 Summary: "Experts Discuss Key Updates in Colorectal Cance…

2024 ASCO® Annual Meeting Insights Hub

S. Chakrabarti, A. Shreenivas

ESMO 2024 Insights: The Value of Immune Checkpoint Blockade in MSS/p…

2024 ESMO Annual Meeting Insights Hub

B. Geisler

Developmental Therapeutics Highlights From ASCO® 2024

2024 ASCO® Annual Meeting Insights Hub

G. Sonpavde

Treating KRAS-Mutated mCRC

Ibrahim Sahin

Anti-EGFR Therapy in CRC: How to Manage Toxicities

Ibrahim Sahin

Guidance on Incorporating Anti-EGFR Therapy in 1L CRC Practice

Ibrahim Sahin

2024 Updates on 1L MSI-H/dMMR mCRC and Using ctDNA MRD Testing in Ea…

Total Health

A. Grothey

ASCO® 2024 Insights: "PanaMa Trial - FU/FA Maintenance Therapy With …

2024 ASCO® Annual Meeting Insights Hub

D. Modest

ASCO® 2024 Summary: "Fruquintinib in Refractory mCRC"

2024 ASCO® Annual Meeting Insights Hub

C. Eng